Navigation Links
ALVESCO(R) Gains FDA Approval for the U.S. Market
Date:1/16/2008

ALVESCO(R) (ciclesonide) Inhalation Aerosol Approved by FDA for the Maintenance and Prophylactic Treatment of Asthma in Patients 12 years of

Age and Older

ALVESCO(R) Will be Commercialised by U.S. Partner

ZURICH, Switzerland, January 16 /PRNewswire/ -- Nycomed announced today that the Food and Drug Administration (FDA) approved ALVESCO(R) (ciclesonide) Inhalation Aerosol in the United States for the maintenance treatment of asthma and as prophylactic therapy in adult and adolescent patients aged 12 years and older. ALVESCO(R) is an inhaled corticosteroid with novel release and distribution properties. Commercialisation and marketing of ALVESCO(R) will be achieved through a U.S. commercial partner.

The decision of the FDA allows the product to be sold in the largest pharmaceutical market in the world, where it is patent protected until 2017. Nycomed is in active negotiations with possible marketing partners for the commercialisation of ALVESCO(R) in the United States. The outlicensing strategy in the U.S. is consistent with Nycomed's direction to seek marketing and commercialisation partnerships for the Nycomed's assets in the U.S. market.

"The approval of ALVESCO(R) provides a new and effective treatment option to help patients control their asthma and improve their quality of life, and will be an important treatment option for physicians," said Myron Zitt, MD, chief of allergy and immunology at the Queens Long Island Medical Group in Babylon, N.Y., and clinical associate professor of medicine at the State University of New York, Stony Brook, School of Medicine.

"We are very much looking forward to serving patients in the United States with this innovative drug and build upon the experience we already have gained with ALVESCO(R). This approval certainly adds to the respiratory area, which is a key segment for Nycomed to grow", comments Dick Soderberg, Executive Vice President of International Marketing.

About ALVESCO(R)

ALVESCO(R) (ciclesonide) Inhalation Aerosol is a new generation of inhaled corticosteroid that reduces inflammatory processes and is indicated for the use in patients with asthma. ALVESCO(R) has been approved in 45 countries including the U.S. and introduced in 30, with more launches expected in 2008.

ALVESCO(R) is based on the active ingredient ciclesonide which is Nycomed's patented corticosteroid with a novel principle of action. Ciclesonide is a prodrug that is activated by intracellular esterases following oral inhalation. ALVESCO(R) has wide inhibitory activities against multiple inflammatory cell types and chemicals involved in the asthmatic response.

Inhaled corticosteroids (ICS) are regarded today as the gold standard in asthma and allergic rhinitis therapy. They inhibit the activity of pro-inflammatory cells and promote the endogenous production of anti-inflammatory substances. With regular use of these corticosteroids, the inflammation in the lungs and airways that underlies the asthma is attenuated.

In clinical trials, ALVESCO(R) was generally well tolerated. The most common adverse reactions (>3%) were headache, nasopharyngitis, sinusitis, pharyngolarynegeal pain, upper respiratory infection, arthralgia, nasal congestion, pain in the extremities and back pain.

Treatment with orally inhaled corticosteroids may lead to signs or symptoms of hypercorticism, suppression of hypothalamic-pituitary-adrenal (HPA) function and/or suppression of growth in children. Glaucoma, increased intraocular pressure and cataracts have been reported following the administration of inhaled corticosteroids.

ALVESCO(R) (ciclesonide) Inhalation Aerosol is an orally inhaled corticosteroid indicated for the maintenance treatment of asthma as prophylactic therapy in adult patients 12 years of age and older. ALVESCO(R) is NOT indicated for the relief of acute bronchospasm.

About Asthma

Asthma is a chronic lung disease caused by airway inflammation and results in airway constriction in response to certain stimuli. It is characterized by a variety of symptoms including wheezing, coughing and a tightening of the airways, which causes shortness of breath and can be life-threatening(i).

Approximately 22 million Americans have asthma. Annually, the disease is responsible for nearly 2 million emergency room visits and accounts for an estimated $11.5 billion in health care costs(ii). Every day in America 40,000 people miss school or work because of asthma; 30,000 people have an asthma attack; 5,000 people visit the emergency room; 1,000 people are admitted to the hospital; and 11 people die due to their asthma condition(iii).

About Nycomed

Nycomed is a pharmaceutical company that provides medicines for hospitals, specialists and general practitioners, as well as over-the-counter medicines in selected markets.

The company is active within a range of therapeutic areas, including cardiology, gastroenterology, osteoporosis, respiratory, pain and tissue management. New products are sourced both from own research and from external partners. Operating throughout Europe and in fast-growing markets such as Latin America, Russia/CIS and the Asia-Pacific region, Nycomed has a presence in about 50 markets worldwide.

Privately owned, the combined group had annual sales of approximately EUR 3.4 billion and an EBITDA of EUR 933.4 million (2006 results).
For more information visit http://www.nycomed.com

Contact:

U.S. media:

Renee Martin / Ashley Altieri

Spectrum Science Communications

Phone: +1-202-955-6222 / Washington, DC

Media:

Tobias Cottmann

Director External Communications

Phone: +41-44-555-15-10

Investors:

Christian B. Seidelin

Vice President Controlling

Treasury and Insurance

Phone: +41-44-555-11-04

---------------------------------

(i) National Heart Lung Blood Institute (NHLBI)

(ii) American Academy of Allergy, Asthma and Immunology, Asthma Statistics (iii) American Academy of Allergy, Asthma and Immunology, Asthma Statistics


'/>"/>
SOURCE Nycomed International Management GmbH
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
2. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
3. Former Banc of America Securities Analyst David Maris Comments on Decision by Biovail to Drop Its Claims Against Him; Denies That He is Cooperating With Biovail
4. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
5. Shareholder Class Action Filed Against LCA-Vision, Inc. by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
6. N-Viro International Corporation Announces Dismissal of Lawsuit Against It
7. Hospitals Adopt STERIS Advanced Room Sterilization Technology in the Fight Against Superbugs
8. Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge
9. Daval International Limited Gains Approval for Phase IIB Trial of AIMSPRO(R)
10. NOLabs AB Achieves Break-Through in Fight Against MRSA-Bacteria
11. Cystic Fibrosis: License Agreement Boosts Development of Therapy Against Lung Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)...  Nurse practitioners play a crucial role in helping patients ... Merck Manuals survey released today. The survey of 210 ... (88 percent) believe they spend at least half of appointment ... ... Manuals survey of 210 nurse practitioners finds that 78% of ...
(Date:7/25/2017)... ... July 25, 2017 , ... ... Executive Director of Strategic Planning. His extensive background in consulting, development and ... experience encompasses marketing and differentiation consulting, business strategy development, new product marketing ...
(Date:7/24/2017)... MA (PRWEB) , ... July 24, 2017 , ... Charm ... has been accepted by the National Conference on Interstate Milk Shipments (NCIMS) Laboratory Committee ... Pilot Program, set to launch July 1, 2017. , The NCIMS voted at its ...
(Date:7/24/2017)... Bridgewater, New Jersey (PRWEB) , ... July 24, ... ... identifies staffing firms across the US and Canada who have proven their superior ... 2017 assessment, Inavero identified Spearhead Staffing as an industry leader based on service ...
Breaking Biology Technology:
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/30/2017)... KONG , March 30, 2017 The ... a system for three-dimensional (3D) fingerprint identification by adopting ground breaking ... into a new realm of speed and accuracy for use in ... at an affordable cost. ... ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
Breaking Biology News(10 mins):